Panmure Gordon Analyst Dr Mike Mitchell said of Allergy Therapeutics today “Investors following Allergy’s peers will have noted the evolving news this month relating to Stallergenes, which reported a suspension of manufacturing at its Antony (France) plant in early December due to problems encountered in the launch of a new IT business operations system. Press reports of a recall of all products released from the site since August suggest, to us, there is likely to be some upside opportunity for Stallergene’s competitors. We’ve highlighted Allergy’s ongoing market share gains against a flat European backdrop – we consider this additional dynamic might also provide some (temporary) tailwind effect in certain product categories. We maintain our investment thesis unchanged.”
Campaign launched to prevent food allergy-related deaths and illness on Teesside
A new campaign has been launched with the aim of preventing food allergy-related illness and deaths across Teesside. Targeted at restaurants and food outlets, all 12 local authorities in the North East have joined forces to